<?xml version="1.0" encoding="UTF-8"?>
<OAI-PMH xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
  <responseDate>2024-05-03T02:08:24Z</responseDate>
  <request verb="GetRecord" identifier="oai:pubmedcentral.nih.gov:10099063" metadataPrefix="pmc">https:/www.ncbi.nlm.nih.gov/pmc/oai/oai.cgi</request>
  <GetRecord>
    <record>
      <header>
        <identifier>oai:pubmedcentral.nih.gov:10099063</identifier>
        <datestamp>2023-04-14</datestamp>
        <setSpec>jamasd</setSpec>
        <setSpec>pmc-open</setSpec>
      </header>
      <metadata>
        <article xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xsi:schemaLocation="https://jats.nlm.nih.gov/ns/archiving/1.3/ https://jats.nlm.nih.gov/archiving/1.3/xsd/JATS-archivearticle1-3.xsd" dtd-version="1.3" xml:lang="en" article-type="research-article">
          <processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats">
            <restricted-by>pmc</restricted-by>
          </processing-meta>
          <front>
            <journal-meta>
              <journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id>
              <journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id>
              <journal-title-group>
                <journal-title>JAMA Network Open</journal-title>
              </journal-title-group>
              <issn pub-type="epub">2574-3805</issn>
              <publisher>
                <publisher-name>American Medical Association</publisher-name>
              </publisher>
            </journal-meta>
            <article-meta>
              <article-id pub-id-type="accession">PMC10099063</article-id>
              <article-id pub-id-type="pmcid">PMC10099063</article-id>
              <article-id pub-id-type="pmc-uid">10099063</article-id>
              <article-id pub-id-type="pmid">37043203</article-id>
              <article-id pub-id-type="pmid">37043203</article-id>
              <article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.7099</article-id>
              <article-id pub-id-type="publisher-id">zoi230235</article-id>
              <article-categories>
                <subj-group subj-group-type="category" specific-use="electronic">
                  <subject>Research</subject>
                </subj-group>
                <subj-group subj-group-type="heading">
                  <subject>Original Investigation</subject>
                </subj-group>
                <subj-group subj-group-type="online-only">
                  <subject>Online Only</subject>
                </subj-group>
                <subj-group subj-group-type="subject-area">
                  <subject>Substance Use and Addiction</subject>
                </subj-group>
              </article-categories>
              <title-group>
                <article-title>Effectiveness of Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder</article-title>
                <subtitle>A Randomized Clinical Trial</subtitle>
                <alt-title alt-title-type="headline">Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder</alt-title>
                <alt-title alt-title-type="running-head">Conditioned Open-label Placebo With Methadone in Treatment of Opioid Use Disorder</alt-title>
              </title-group>
              <contrib-group>
                <contrib contrib-type="author" corresp="yes">
                  <name>
                    <surname>Belcher</surname>
                    <given-names>Annabelle M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230235aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Cole</surname>
                    <given-names>Thomas O.</given-names>
                  </name>
                  <degrees>MA</degrees>
                  <xref rid="zoi230235aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Massey</surname>
                    <given-names>Ebonie</given-names>
                  </name>
                  <degrees>MA</degrees>
                  <xref rid="zoi230235aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Billing</surname>
                    <given-names>Amy S.</given-names>
                  </name>
                  <degrees>MSSA</degrees>
                  <xref rid="zoi230235aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wagner</surname>
                    <given-names>Michael</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230235aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wooten</surname>
                    <given-names>William</given-names>
                  </name>
                  <degrees>MS</degrees>
                  <xref rid="zoi230235aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Epstein</surname>
                    <given-names>David H.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230235aff4" ref-type="aff">
                    <sup>4</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Hoag</surname>
                    <given-names>Stephen W.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230235aff5" ref-type="aff">
                    <sup>5</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wickwire</surname>
                    <given-names>Emerson M.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230235aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                  <xref rid="zoi230235aff6" ref-type="aff">
                    <sup>6</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Greenblatt</surname>
                    <given-names>Aaron D.</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230235aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Colloca</surname>
                    <given-names>Luana</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230235aff7" ref-type="aff">
                    <sup>7</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Rotrosen</surname>
                    <given-names>John</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230235aff8" ref-type="aff">
                    <sup>8</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Magder</surname>
                    <given-names>Lawrence</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230235aff3" ref-type="aff">
                    <sup>3</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Weintraub</surname>
                    <given-names>Eric</given-names>
                  </name>
                  <degrees>MD</degrees>
                  <xref rid="zoi230235aff1" ref-type="aff">
                    <sup>1</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Wish</surname>
                    <given-names>Eric D.</given-names>
                  </name>
                  <degrees>PhD</degrees>
                  <xref rid="zoi230235aff2" ref-type="aff">
                    <sup>2</sup>
                  </xref>
                </contrib>
                <contrib contrib-type="author">
                  <name>
                    <surname>Kaptchuk</surname>
                    <given-names>Ted J.</given-names>
                  </name>
                  <xref rid="zoi230235aff9" ref-type="aff">
                    <sup>9</sup>
                  </xref>
                </contrib>
              </contrib-group>
              <aff id="zoi230235aff1"><label>1</label>Department of Psychiatry, University of Maryland School of Medicine, Baltimore</aff>
              <aff id="zoi230235aff2"><label>2</label>Center for Substance Abuse Research, University of Maryland, College Park</aff>
              <aff id="zoi230235aff3"><label>3</label>Department of Epidemiology and Public Health, University of Maryland School of Medicine, Baltimore</aff>
              <aff id="zoi230235aff4"><label>4</label>Real-World Assessment, Prediction, and Treatment Unit, National Institute on Drug Abuse Intramural Research Program, Baltimore, Maryland</aff>
              <aff id="zoi230235aff5"><label>5</label>Applied Pharmaceutics Lab, University of Maryland School of Pharmacy, Baltimore</aff>
              <aff id="zoi230235aff6"><label>6</label>Sleep Disorders Center, Division of Pulmonary and Critical Care Medicine, University of Maryland School of Medicine, Baltimore</aff>
              <aff id="zoi230235aff7"><label>7</label>Pain and Translational Symptom Science, University of Maryland School of Nursing, Baltimore</aff>
              <aff id="zoi230235aff8"><label>8</label>Department of Psychiatry, NYU Grossman School of Medicine, New York, New York</aff>
              <aff id="zoi230235aff9"><label>9</label>Program in Placebo Studies, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts</aff>
              <author-notes>
                <title>Article Information</title>
                <p><bold>Accepted for Publication:</bold> February 23, 2023.</p>
                <p content-type="published-online"><bold>Published:</bold> April 12, 2023. <?xpp bx;1?>doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.7099</uri></p>
                <p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. © 2023 Belcher AM et al. <italic>JAMA Network Open</italic>.</p>
                <corresp id="zoi230235cor1"><bold>Corresponding Author:</bold> Annabelle M. Belcher, PhD, Division of Addiction Research and Treatment, University of Maryland School of Medicine, 1001 W Pratt St, Baltimore, MD 21223 (<email xlink:href="abelcher@som.umaryland.edu">abelcher@som.umaryland.edu</email>).</corresp>
                <p content-type="author-contributions"><bold>Author Contributions:</bold> Dr Belcher had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.</p>
                <p><italic>Concept and design:</italic> Belcher, Epstein, Hoag, Greenblatt, Colloca, Weintraub, Wish, Kaptchuk.</p>
                <p><italic>Acquisition, analysis, or interpretation of data:</italic> Belcher, Cole, Massey, Billing, Wagner, Wooten, Epstein, Wickwire, Rotrosen, Magder, Wish, Kaptchuk.</p>
                <p><italic>Drafting of the manuscript:</italic> Belcher, Billing, Wooten, Hoag, Magder, Kaptchuk.</p>
                <p><italic>Critical revision of the manuscript for important intellectual content:</italic> Belcher, Cole, Massey, Wagner, Epstein, Wickwire, Greenblatt, Colloca, Rotrosen, Weintraub, Wish, Kaptchuk.</p>
                <p><italic>Statistical analysis:</italic> Belcher, Massey, Wagner, Wooten, Epstein, Colloca, Magder, Wish.</p>
                <p><italic>Obtained funding:</italic> Belcher, Colloca, Kaptchuk.</p>
                <p><italic>Administrative, technical, or material support:</italic> Belcher, Cole, Billing, Hoag, Greenblatt, Weintraub, Wish, Kaptchuk.</p>
                <p><italic>Supervision:</italic> Belcher, Greenblatt, Colloca, Weintraub, Wish, Kaptchuk.</p>
                <p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Wickwire reported receiving personal fees from Eisai, Ensodata, Primasun, Purdue, and ResMed; and grants from Merck, ResMed, and ResMed Foundation outside the submitted work; in addition, Dr Wickwire is an equity shareholder for WellTap issued software copyright. No other disclosures were reported.</p>
                <p content-type="funding-statement"><bold>Funding/Support:</bold> This work was supported by the Foundation for the Science of the Therapeutic Encounter (Drs Belcher and Colloca) and funds from the University of Maryland MPowering the State Opioid Use Disorders Initiative (Dr Wish. and Asaf Keller, PhD). Additional support was provided by the University of Maryland, Baltimore, Institute for Clinical &amp; Translational Research and the National Center for Advancing Translational Sciences Clinical Translational Science Award grant 1UL1TR003098.</p>
                <p><bold>Role of the Funder/Sponsor:</bold> The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p>
                <p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI230235-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p>
                <p><bold>Additional Contributions:</bold> We acknowledge and gratefully thank the medical (nursing and physician) and counseling staff at the University of Maryland Addiction Treatment Center for their help and insight on study implementation: Denesha Pendleton, RN, Khadijar Woodward, LPN, Bertha Eno, LPN, Tara Driscoll, RN, AD, and in particular, Raymond Velencia, MS, MBA, for invaluable help and advice during the running of the trial. We also acknowledge Christopher Welsh, MD, and Jewell Benford, LCSW, both from the University of Maryland School of Medicine, Department of Psychiatry, for early helpful comments on study design during trial planning, and thank Zofia Kozak, MD, Riti Kotamarti, MD, Olivia Pettingill, JD, Brianna Osei, MS, Jonathan Lewis, BA, and Julie Factor, RN, for help with running aspects of the trial, participant contact, and data curation. No financial compensation was provided. We also thank the patient participants for their involvement in the study and acknowledge their strength and bravery in their ongoing struggle with addiction.</p>
              </author-notes>
              <pub-date pub-type="epub" iso-8601-date="2023-04-12T10:00">
                <day>12</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="collection">
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <pub-date pub-type="pmc-release">
                <day>12</day>
                <month>4</month>
                <year>2023</year>
              </pub-date>
              <!--PMC Release delay is 0 months and 0 days and was based on the <pub-date pub-type="epub"/>.-->
              <volume>6</volume>
              <issue>4</issue>
              <elocation-id>e237099</elocation-id>
              <history>
                <date date-type="received">
                  <day>16</day>
                  <month>9</month>
                  <year>2022</year>
                </date>
                <date date-type="accepted">
                  <day>23</day>
                  <month>2</month>
                  <year>2023</year>
                </date>
              </history>
              <permissions>
                <copyright-statement>Copyright 2023 Belcher AM et al. <italic>JAMA Network Open</italic>.</copyright-statement>
                <license>
                  <ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref>
                  <license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p>
                </license>
              </permissions>
              <self-uri content-type="pdf-version" xlink:href="jamanetwopen-e237099.pdf">jamanetwopen-e237099.pdf</self-uri>
              <self-uri content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.7099"/>
              <abstract abstract-type="key-points">
                <title>Key Points</title>
                <sec id="ab-zoi230235-1">
                  <title>Question</title>
                  <p>Can conditioned open-label placebo (C-OLP) help increase the efficacy of treatment with methadone for opioid use disorder?</p>
                </sec>
                <sec id="ab-zoi230235-2">
                  <title>Findings</title>
                  <p>In this 2-group, single-blind randomized clinical trial including 131 individuals, 90-day retention in treatment and quality of sleep were significantly improved with C-OLP vs treatment as usual. Methadone dose, the prespecified primary outcome, did not differ significantly between groups.</p>
                </sec>
                <sec id="ab-zoi230235-3">
                  <title>Meaning</title>
                  <p>The findings of this trial suggest that C-OLP may improve opioid use disorder treatment outcomes; further exploration of C-OLP as an inexpensive, low-risk adjunct to methadone treatment may be beneficial.</p>
                </sec>
              </abstract>
              <abstract>
                <sec id="ab-zoi230235-4">
                  <title>Importance</title>
                  <p>Methadone treatment is the most effective evidence-based treatment for opioid use disorder (OUD), but challenges related to dosing and premature treatment dropout argue for adjunct interventions to improve outcomes. One potential behavioral intervention with low risk involves harnessing placebo effects.</p>
                </sec>
                <sec id="ab-zoi230235-5">
                  <title>Objective</title>
                  <p>To determine the effect of a pharmacologically conditioned open-label placebo (C-OLP) on 90-day methadone dose, retention, drug use, withdrawal, craving, quality of life, and sleep.</p>
                </sec>
                <sec id="ab-zoi230235-6">
                  <title>Design, Setting, and Participants</title>
                  <p>This 2-arm, open-label, single-blind randomized clinical trial was conducted between December 5, 2017, and August 2, 2019, in an academically affiliated community opioid treatment program. Analyses were conducted between October 1, 2019, and April 30, 2020. A total of 320 newly enrolled adults seeking treatment for moderate to severe OUD were assessed for study eligibility; 131 met eligibility criteria, provided informed consent, and were randomized to either C-OLP or treatment as usual (TAU) in an unequal-block (3:2) manner. Exclusion criteria were pregnancy, hospital/program transfers, and court-ordered treatment.</p>
                </sec>
                <sec id="ab-zoi230235-7">
                  <title>Interventions</title>
                  <p>Participants randomized to C-OLP received pharmacologic conditioning and a placebo pill and methadone, and participants randomized to TAU were given methadone only. Participants met with the study team 5 times: at baseline (treatment intake) and 2, 4, 8, and 12 weeks postbaseline. Interactions were balanced between the 2 groups.</p>
                </sec>
                <sec id="ab-zoi230235-8">
                  <title>Main Outcomes and Measures</title>
                  <p>Outcomes included 90-day methadone dose (primary) and treatment retention, drug use, withdrawal, craving, quality of life, and sleep quality (secondary). Analyses were conducted as intention-to-treat.</p>
                </sec>
                <sec id="ab-zoi230235-9">
                  <title>Results</title>
                  <p>Of the 131 people enrolled in the study, 54 were randomized to TAU and 77 to C-OLP. Mean (SD) age was 45.9 (11.2) years; most of the participants were Black or African American (83 [63.4%]) and male (84 [64.1%]). No significant group differences were observed in the mean (SD) 90-day methadone dose (83.1 [25.1] mg for group TAU, 79.4 [19.6] mg for group C-OLP; <italic>t</italic> = 0.6219<sub>91</sub>; <italic>P</italic> = .43), but the groups differed significantly in their retention rates: 33 (61.1%) for TAU and 60 (77.9%) for C-OLP (χ<sup>2</sup><sub>1</sub> = 4.356; <italic>P</italic> = .04; number needed to treat for the beneficial outcome of 3-month treatment retention, 6; 95% CI, 4-119). C-OLP participants also reported significantly better sleep quality.</p>
                </sec>
                <sec id="ab-zoi230235-10">
                  <title>Conclusions and Relevance</title>
                  <p>In this randomized clinical trial, C-OLP had no effect on the primary outcome of 90-day methadone dose. However, C-OLP participants were significantly more likely to remain in treatment. These findings support the use of C-OLP as a methadone treatment adjunct, but larger trials are needed to further examine the use of C-OLP.</p>
                </sec>
                <sec id="ab-zoi230235-11">
                  <title>Trial Registration</title>
                  <p>ClinicalTrials.gov Identifier: <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT02941809" ext-link-type="uri">NCT02941809</ext-link></p>
                </sec>
              </abstract>
              <abstract abstract-type="teaser" specific-use="electronic">
                <p>This randomized clinical trial examines the use of a pharmacologically conditioned open-label placebo in treatment of opioid use disorder.</p>
              </abstract>
            </article-meta>
          </front>
          <body>
            <sec id="H1-1-ZOI230235">
              <title>Introduction</title>
              <p>First-line treatments for opioid use disorder (OUD) include medications,<sup><xref rid="zoi230235r1" ref-type="bibr">1</xref></sup> with one of these—methadone—possessing the largest evidence base for decreased drug use and crime and increased health improvement.<sup><xref rid="zoi230235r2" ref-type="bibr">2</xref>,<xref rid="zoi230235r3" ref-type="bibr">3</xref>,<xref rid="zoi230235r4" ref-type="bibr">4</xref></sup> But given the high-dose adverse effects (eg, constipation, nausea, or more seriously, cardiac arrhythmia),<sup><xref rid="zoi230235r5" ref-type="bibr">5</xref></sup> strategies rendering methadone effective at lower dosages are needed.</p>
              <p>One possible intervention involves the harnessing of placebo effects. Broadly defined, placebo effects are improvements in symptoms attributable to the therapeutic encounter<sup><xref rid="zoi230235r6" ref-type="bibr">6</xref></sup> and thought to be mediated principally by expectation and conditioning<sup><xref rid="zoi230235r7" ref-type="bibr">7</xref></sup> and emergent theories, such as bayesian brain.<sup><xref rid="zoi230235r8" ref-type="bibr">8</xref></sup> Although there has been great appreciation for the potential benefits of placebos, enthusiasm has been dampened by the perception that deception is required,<sup><xref rid="zoi230235r8" ref-type="bibr">8</xref></sup> which would violate ethical norms of autonomy, respect, and informed consent. Recent randomized clinical trials (RCTs), mainly in patients with primary pain and other disorders,<sup><xref rid="zoi230235r9" ref-type="bibr">9</xref></sup> have shown, however, that deception may be unnecessary for clinically meaningful placebo effects.<sup><xref rid="zoi230235r10" ref-type="bibr">10</xref>,<xref rid="zoi230235r11" ref-type="bibr">11</xref></sup> In these open-label placebo (OLP) studies, placebos are clearly identified as such and have been shown to improve outcomes for irritable bowel syndrome,<sup><xref rid="zoi230235r12" ref-type="bibr">12</xref>,<xref rid="zoi230235r13" ref-type="bibr">13</xref>,<xref rid="zoi230235r14" ref-type="bibr">14</xref></sup> chronic pain,<sup><xref rid="zoi230235r15" ref-type="bibr">15</xref>,<xref rid="zoi230235r16" ref-type="bibr">16</xref>,<xref rid="zoi230235r17" ref-type="bibr">17</xref>,<xref rid="zoi230235r18" ref-type="bibr">18</xref></sup> allergic rhinitis,<sup><xref rid="zoi230235r19" ref-type="bibr">19</xref>,<xref rid="zoi230235r20" ref-type="bibr">20</xref></sup> migraine,<sup><xref rid="zoi230235r21" ref-type="bibr">21</xref></sup> cancer-related fatigue,<sup><xref rid="zoi230235r22" ref-type="bibr">22</xref>,<xref rid="zoi230235r23" ref-type="bibr">23</xref></sup> and menopausal hot flushes.<sup><xref rid="zoi230235r24" ref-type="bibr">24</xref></sup> Patients are not told the placebo will work—rather, they are informed of the possible benefits of OLPs, using data from RCTs. Frequently, these studies implement a 4-point script to provide a description, putative mechanisms, and automatic nature of OLP, and to underscore the importance of placebo adherence.<sup><xref rid="zoi230235r25" ref-type="bibr">25</xref></sup></p>
              <p>An additional method of harnessing placebo effects implements pharmacologic (pavlovian) conditioning, wherein a medication’s therapeutic effects are conferred to placebos following repeated pairings with the drug.<sup><xref rid="zoi230235r26" ref-type="bibr">26</xref>,<xref rid="zoi230235r27" ref-type="bibr">27</xref>,<xref rid="zoi230235r28" ref-type="bibr">28</xref>,<xref rid="zoi230235r29" ref-type="bibr">29</xref>,<xref rid="zoi230235r30" ref-type="bibr">30</xref>,<xref rid="zoi230235r31" ref-type="bibr">31</xref>,<xref rid="zoi230235r32" ref-type="bibr">32</xref></sup> This approach has been used in studies with a primary aim of medication reduction<sup><xref rid="zoi230235r33" ref-type="bibr">33</xref>,<xref rid="zoi230235r34" ref-type="bibr">34</xref>,<xref rid="zoi230235r35" ref-type="bibr">35</xref>,<xref rid="zoi230235r36" ref-type="bibr">36</xref>,<xref rid="zoi230235r37" ref-type="bibr">37</xref></sup> and has been shown to treat symptoms of psoriasis,<sup><xref rid="zoi230235r38" ref-type="bibr">38</xref></sup> insomnia,<sup><xref rid="zoi230235r39" ref-type="bibr">39</xref></sup> allergic rhinitis,<sup><xref rid="zoi230235r40" ref-type="bibr">40</xref></sup> attention-deficit/hyperactivity disorder,<sup><xref rid="zoi230235r33" ref-type="bibr">33</xref>,<xref rid="zoi230235r34" ref-type="bibr">34</xref></sup> immune suppression after kidney transplant,<sup><xref rid="zoi230235r41" ref-type="bibr">41</xref></sup> and postsurgical pain.<sup><xref rid="zoi230235r37" ref-type="bibr">37</xref></sup> To our knowledge, no studies have been conducted on either paradigm (OLP or pharmacologically conditioned placebos) or their combination for OUD. The goal of the present study was to evaluate the effect of a pharmacologically conditioned OLP (C-OLP) pill on 90-day methadone treatment outcomes, including the dose of methadone (primary) and methadone treatment retention, drug use, withdrawal, craving, quality of life, and quality of sleep (secondary). We hypothesized C-OLP would obviate the need for methadone dose escalations—an effect that would translate to a lower mean 90-day methadone dose.</p>
            </sec>
            <sec id="H1-2-ZOI230235">
              <title>Methods</title>
              <p>This single-site RCT was conducted between December 5, 2017, and August 2, 2019. Written informed consent was obtained from all participants. The trial protocol (<xref rid="note-ZOI230235-1-s" ref-type="supplementary-material">Supplement 1</xref>) was approved by the institutional review board at the University of Maryland, Baltimore, and a revised version was published as a peer-reviewed article.<sup><xref rid="zoi230235r42" ref-type="bibr">42</xref></sup> This study report adheres to the Consolidated Standards of Reporting Trials (<ext-link xlink:href="https://www.equator-network.org/reporting-guidelines/consort/" ext-link-type="uri">CONSORT</ext-link>) 2010 reporting guideline.<sup><xref rid="zoi230235r43" ref-type="bibr">43</xref></sup></p>
              <sec id="H2-1-ZOI230235">
                <title>Setting and Participants</title>
                <p>Adults seeking treatment for OUD were recruited from an urban, community-based, academically affiliated opioid treatment program. All participants met <italic>Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition</italic>,<sup><xref rid="zoi230235r44" ref-type="bibr">44</xref></sup> criteria for moderate to severe OUD and were new (same-day) adult initiates for methadone treatment. Exclusions were pregnancy, other clinic or hospital transfer, and court-ordered treatment.</p>
              </sec>
              <sec id="H2-2-ZOI230235">
                <title>Study Design and Procedures</title>
                <p>The 12-week study included 5 individual meetings with study staff at baseline entry into treatment, and 2, 4, 8, and 12 weeks postbaseline. Participants received $25 incentives for each meeting. New patients were recruited on their first day of methadone treatment. At the end of the initial intake procedures, a member of the study team approached interested participants to obtain informed consent and completion of in-person survey and assessment. As in previous studies,<sup><xref rid="zoi230235r25" ref-type="bibr">25</xref></sup> a script was used as a conversational guide to emphasize 4 points: (1) a brief description of the positive impact of placebo in RCTs; (2) the automatic nature of placebo responses, with a description appropriate for lay persons of the neurobiological and psychological (conditioning) mechanisms of associative learning; (3) the lack of a requirement of belief that the placebo would work; and (4) emphasis on the criticality of placebo consumption (<xref rid="note-ZOI230235-1-s" ref-type="supplementary-material">Supplement 1</xref> and eTable in <xref rid="note-ZOI230235-1-s" ref-type="supplementary-material">Supplement 2</xref>). Participants then viewed a video of a television news piece that described scientific studies of OLP interventions to treat irritable bowel syndrome.<sup><xref rid="zoi230235r45" ref-type="bibr">45</xref></sup> Participant characteristic data (sex, race and ethnicity) were collected as part of the baseline drug use history and assessment survey. For demographic characterization of the samples, participants self-identified their sex (female, male, other), race (selection of ≥1 of the following categories: American Indian or Alaskan Native, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, other), and ethnicity (Hispanic or Latinx: yes or no). Participants were then randomly assigned to either C-OLP or treatment as usual (TAU), were provided their observed methadone dose and, for those randomized to the intervention, a placebo pill. All group interactions with study staff were balanced for length and content, and the same outcome assessments were provided to both groups. C-OLP participants were not provided boosters or additional information regarding the rationale of the study beyond what was presented at the baseline meeting (the same content provided to TAU participants).</p>
              </sec>
              <sec id="H2-3-ZOI230235">
                <title>Placebo Intervention and Open-label Conditioning Procedures</title>
                <p>The intervention consisted of 2 phases: once-daily placebo conditioning (phase I, first 2 weeks) and twice-daily placebo (phase II, week 3 up to 3 months) (<xref rid="note-ZOI230235-1-s" ref-type="supplementary-material">Supplement 1</xref>). We chose to implement a 2-phase protocol for the following reasons: (1) previous research showing that placebo responses scale with the amount of associative training delivered<sup><xref rid="zoi230235r26" ref-type="bibr">26</xref>,<xref rid="zoi230235r46" ref-type="bibr">46</xref></sup>; (2) best clinical practice with methadone involves a titration protocol—low doses early in treatment that are gradually increased to maintenance levels<sup><xref rid="zoi230235r47" ref-type="bibr">47</xref></sup>—a protocol that would theoretically diminish the creation of a positive placebo response if conditioning were restricted to only a few days of methadone induction; and (3) research showing that the first 3 months of methadone treatment represent the most vulnerable period for dropout.<sup><xref rid="zoi230235r48" ref-type="bibr">48</xref>,<xref rid="zoi230235r49" ref-type="bibr">49</xref></sup></p>
              </sec>
              <sec id="H2-4-ZOI230235">
                <title>Clinic Urine Screen</title>
                <p>Results from clinic urine drug screens (QuickTox panel; LabCorp) were logged at baseline by study staff. Substances tested included opiates, cocaine, methamphetamine, tetrahydrocannabinol, amphetamine, phencyclidine, benzodiazepine, barbiturates, methadone, oxycodone, methylenedioxymethamphetamine, buprenorphine, and fentanyl.</p>
              </sec>
              <sec id="H2-5-ZOI230235">
                <title>Outcomes</title>
                <p>The primary outcome was 3-month (90th-day) milligram methadone dose. Secondary outcome measures included treatment retention, self-reported drug use, opioid withdrawal, craving, quality of life, and sleep. Outcomes were assessed in person via facilitated self-report at all 5 time points, except sleep (measured only at baseline and 1 and 3 months postbaseline).</p>
                <p>Three-month retention was assessed as a binomial variable (in treatment at day 90, yes or no). For descriptive purposes, retention was also counted as the number of days retained in treatment, from intake to day 90. We adopted the clinic’s definition of dropout (30 continuous absent days), with the last clinic visit considered the final day in treatment.</p>
                <p>Drug use was assessed via self-report of past 2-week use of 4 common substances: opioids (including heroin, fentanyl, nonprescribed opioids), cocaine, benzodiazepines, and alcohol; other was a fifth category. Total days used (out of 14) was recorded.</p>
                <p>Withdrawal was assessed using the objective (range, 0-13) and subjective Opiate Withdrawal Scales. Scores range from 0 to 64, with higher scores on these scales indicating greater withdrawal symptom severity.<sup><xref rid="zoi230235r50" ref-type="bibr">50</xref></sup></p>
                <p>A craving assessment adapted from previous studies<sup><xref rid="zoi230235r51" ref-type="bibr">51</xref>,<xref rid="zoi230235r52" ref-type="bibr">52</xref></sup> was used to measure self-reported craving intensity, using a 0 to 100 visual analog scale. Higher values indicate greater levels of craving.</p>
                <p>Quality of life was assessed using the Abbreviated World Health Organization Quality of Life assessment. Scores range from 0 to 100, with higher scores indicating higher quality of life).<sup><xref rid="zoi230235r53" ref-type="bibr">53</xref></sup></p>
                <p>Sleep was measured using the Pittsburgh Sleep Quality Index (PSQI. Scores range from 0 to 21, with higher scores indicating worse quality of sleep.<sup><xref rid="zoi230235r54" ref-type="bibr">54</xref></sup></p>
              </sec>
              <sec id="H2-6-ZOI230235">
                <title>Sample Size</title>
                <p>Power was calculated a priori for the primary outcome of the 3-month (90-day) dose of methadone. We anticipated that dose escalations after initial titration would be recommended for approximately 70% of participants in the TAU cohort in that time frame, basing this approximation on discussions with clinic staff on the proportion of patients who receive dose increases at this opioid treatment program. Thus, 60 participants per group would yield a power of 0.80 to detect a group difference if the corresponding rate in the intervention group was 44% or lower (a maximum of 26 of 60 participants), using a Fisher exact test with a 2-tailed α level of .05. This is equivalent to an odds ratio of 3.03 or a Cohen <italic>d</italic> value of 0.61.</p>
              </sec>
              <sec id="H2-7-ZOI230235">
                <title>Randomization</title>
                <p>Randomization was performed by a blinded member of the investigation team (L.C.) not directly involved with daily study procedures. A computer-generated random number sequence with unequal block randomization (60% intervention, 40% control) was created, stratified by sex, and placed into sequentially numbered opaque envelopes (n = 30/group/sex for a total of 120 random allocations). Group allocation occurred after day 1 assessment and just before the first dose of methadone with an assignment reveal.</p>
              </sec>
              <sec id="H2-8-ZOI230235">
                <title>Blinding</title>
                <p>At all stages of the study, methadone dose adjustments (ie, manipulations of the primary outcome) were overseen by addiction medicine physicians blinded to treatment allocation. Physicians, nurse practitioners, and counselors were also blinded, as were data analysts. Other study team members were blinded for all of day 1.</p>
              </sec>
              <sec id="H2-9-ZOI230235">
                <title>Statistical Analysis</title>
                <p>Analyses were conducted between October 1, 2019, and April 30, 2020. Outcomes were analyzed in accordance with randomization assignments, following an intention-to-treat approach. Descriptive statistics with central tendencies and spread were used for continuous variables; distributions and percentages were used for categorical variables. Unpaired <italic>t</italic> tests were used to assess group differences in mean 90th-day methadone dose (primary outcome) and mean 90th-day methadone dose in the stable-dose subgroup (subanalysis 1).</p>
                <p>We adopted a second, more stringent analysis (subanalysis 1) to account for the potential barrier to analyzing group differences on the 90th-day methadone dose: a missed dose on the 90th day or a temporary need for a lower dose on that day due to 2 or more consecutive missed days (in line with standard opioid treatment program dosing protocols) just before the 90th day would preclude a stabilization dose of methadone, which would have potentially hidden any group differences. This analysis included only participants who had been retained for 90 days, who missed no days within the last 14 days preceding the 90th day, and whose daily dose of methadone had been stable for the 2 weeks before day 90. The rationale was that this would allow sufficient time for any therapeutically necessary dose changes to occur. We then assessed between-group differences in mean 90-day methadone dose for stable-dose participants.</p>
                <p>Group differences were tested with χ<sup>2</sup> analysis for the secondary outcome of treatment retention (continuous, up to 90 days). To illustrate the difference between the groups with respect to timing of dropout, we constructed survival curves for the distribution of time to dropout, using the Kaplan-Meier approach. We also expressed this as the number needed to treat for the beneficial outcome of 3-month treatment retention. Mixed-effects longitudinal regression models were used for all remaining secondary outcomes, including drug use, withdrawal, craving, quality of life, and sleep (global PSQI scores). All tests were 2-tailed, with an α threshold of significance set at .05. Data were stored on REDCap,<sup><xref rid="zoi230235r55" ref-type="bibr">55</xref></sup> and analyses were conducted using SPSS, version 27 (IBM Corp) and SAS, version 9.4 (SAS Institute Inc).</p>
              </sec>
            </sec>
            <sec id="H1-3-ZOI230235">
              <title>Results</title>
              <sec id="H2-10-ZOI230235">
                <title>Study Participants</title>
                <p>Among 320 new patients screened for methadone treatment, 131 individuals (mean [SD] age, 45.9 [11.2] years; 84 [64.1%] men; 47 [35.9%] women; 83 [63.4%] Black or African American) met eligibility criteria, provided informed consented, were randomized to receive C-OLP (n = 77) or TAU (n = 54), and completed all of day 1 and baseline procedures (<xref rid="zoi230235t1" ref-type="table">Table 1</xref> and <xref rid="zoi230235f1" ref-type="fig">Figure 1</xref>). Among the 187 assessed individuals who did not meet eligibility criteria, the most common reason was that they had already initiated methadone treatment (n = 119). Forty-nine people declined participation, with most due to time constraints. Seven individuals did not want to add anything to their treatment. Participants reported a mean (SD) of 22.9 (12.8) years of heroin and/or fentanyl use, and 66 (50.4%) reported current intravenous drug use. Two individuals who had provided informed consent were removed from treatment before methadone dosing following intake: one was hospitalized for acute edema and the other was referred for office-based buprenorphine treatment; these individuals’ data are not included in any reported analyses. Three individuals allocated to the C-OLP group who had completed baseline assessments withdrew from the study following 1, 3, and 8 days of intervention.</p>
                <table-wrap position="float" id="zoi230235t1">
                  <label>Table 1. </label>
                  <caption>
                    <title>Participant Baseline Characteristics</title>
                  </caption>
                  <table frame="hsides" rules="groups">
                    <col width="49.3%" span="1"/>
                    <col width="15.48%" span="1"/>
                    <col width="17.8%" span="1"/>
                    <col width="17.42%" span="1"/>
                    <thead>
                      <tr>
                        <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Characteristic</th>
                        <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Patients, No. (%)</th>
                      </tr>
                      <tr>
                        <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">TAU (n = 54)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">C-OLP (n = 77)</th>
                        <th valign="top" align="left" scope="col" rowspan="1" colspan="1">Total (N = 131)</th>
                      </tr>
                    </thead>
                    <tbody>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, mean (SD), y</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43.5 (11.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47.6 (10.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">45.9 (11.2)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (42.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24 (31.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47 (35.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (57.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53 (68.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">84 (64.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black or African American</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">31 (57.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">52 (67.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">83 (63.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (42.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">24 (31.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47 (35.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<xref rid="zoi230235t1n1" ref-type="table-fn"><sup>a</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (1.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Ethnicity (Hispanic or Latinx)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (2.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Past 12-mo income, $</td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &lt;15 000</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">47 (87.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">67 (87.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">114 (87.0)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 15 000-19 999</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (9.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (7.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (8.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> 20 000-39 999</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (3.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (1.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (2.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &gt;40 000</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (3.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (2.3)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Past 12-mo occupation<xref rid="zoi230235t1n2" ref-type="table-fn"><sup>b</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Unemployed</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">29 (53.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">39 (50.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">68 (51.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Retired or disabled</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">13 (24.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19 (24.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32 (24.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Employed parttime</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">4 (7.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">10 (13.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">14 (10.7)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Employed full time</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">2 (3.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (7.8)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (6.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Homemaker/caregiver</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">5 (9.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (3.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">8 (6.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Military service</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (1.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Incarcerated</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">0</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (1.3)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">1 (0.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">No. of years opioid use, mean (SD)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22.4 (12.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23.3 (13.2)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">22.9 (12.8)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1">Intravenous drug use</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">34 (63.0)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">32 (41.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">66 (50.4)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="col" rowspan="1" colspan="1">Positive clinic urine toxicology screen at baseline<xref rid="zoi230235t1n3" ref-type="table-fn"><sup>c</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                        <td valign="top" align="left" rowspan="1" colspan="1"/>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Opiates<xref rid="zoi230235t1n4" ref-type="table-fn"><sup>d</sup></xref></td>
                        <td valign="top" align="left" rowspan="1" colspan="1">53 (98.1)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">69 (89.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">122 (93.1)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Cocaine</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">43 (79.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">52 (67.5)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">95 (72.5)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Methamphetamine</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (5.6)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">3 (3.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">6 (4.6)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Tetrahydrocannabinol</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">11 (20.4)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">19 (24.7)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">30 (22.9)</td>
                      </tr>
                      <tr>
                        <td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Benzodiazepines</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">21 (38.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">23 (29.9)</td>
                        <td valign="top" align="left" rowspan="1" colspan="1">44 (33.6)</td>
                      </tr>
                    </tbody>
                  </table>
                  <table-wrap-foot>
                    <p>Abbreviations: C-OLP, conditioned open-label placebo; TAU, treatment as usual.</p>
                    <fn id="zoi230235t1n1">
                      <label>
                        <sup>a</sup>
                      </label>
                      <p>One individual self-identified as Pacific Islander and White.</p>
                    </fn>
                    <fn id="zoi230235t1n2">
                      <label>
                        <sup>b</sup>
                      </label>
                      <p>Options were not mutually exclusive; 1 participant reported both unemployed and incarcerated.</p>
                    </fn>
                    <fn id="zoi230235t1n3">
                      <label>
                        <sup>c</sup>
                      </label>
                      <p>Data missing from 3 participants who were unable to provide a biological sample on the date of intake. Reported percentages are inclusive of missing data.</p>
                    </fn>
                    <fn id="zoi230235t1n4">
                      <label>
                        <sup>d</sup>
                      </label>
                      <p>Positive for at least 1 of the following drugs: morphine, oxycodone, fentanyl, buprenorphine, or methadone.</p>
                    </fn>
                  </table-wrap-foot>
                </table-wrap>
                <fig position="float" id="zoi230235f1" fig-type="figure">
                  <label>Figure 1. </label>
                  <caption>
                    <title>Flow Diagram of Study Participants</title>
                    <p>C-OLP indicates conditioned open-label placebo; OTP, opioid treatment program; TAU, treatment as usual.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e237099-g001" position="float"/>
                </fig>
              </sec>
              <sec id="H2-11-ZOI230235">
                <title>Primary Outcome: 3-Month Dose of Methadone</title>
                <p>We report findings for all 131 participants in an intention-to-treat analysis. Fifty-four individuals were randomized to TAU, 77 to C-OLP. Starting methadone doses for both groups ranged from 10 to 40 mg (mode = 25 mg). There were no statistically significant differences between the groups in their mean (SD) dose at day 90: 83.1 (25.1) mg for group TAU (n = 33) and 79.4 (19.6) mg for group C-OLP (n = 60) (<italic>t</italic><sub>91</sub> = 0.6219; <italic>P</italic> = .43). Group mean doses were also similar across the first 90 days (<xref rid="zoi230235f2" ref-type="fig">Figure 2</xref>).</p>
                <fig position="float" id="zoi230235f2" fig-type="figure">
                  <label>Figure 2. </label>
                  <caption>
                    <title>Mean Methadone Doses at Various Intervals Up to 90 Days</title>
                    <p>Mean group methadone doses are shown for postentry into treatment. Mean values include data that were available for people retained at each time point. Treatment as usual (TAU): 47 individuals retained at 7 days, 43 at 15 days, 38 at 30 days, 37 at 45 days, 34 at 60 days, and 33 at 90 days. Conditioned open-label placebo (C-OLP): 73 individuals retained at 7 days, 71 at 15 days, 67 at 30 days, 65 at 45 days, 64 at 60 days, and 60 at 90 days. Whiskers indicate 95% CIs.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e237099-g002" position="float"/>
                </fig>
                <p>Subanalysis 1 included only individuals who had maintained a stable dose of methadone during the last 2 weeks of treatment (15 TAU, 32 C-OLP). There was no significant difference between the groups in mean (SD) 90th-day methadone dose (85.3 [13.4] mg for TAU, 87.0 [15.6] mg for C-OLP; t<sub>45</sub> = 0.3621; <italic>P</italic> = .72).</p>
              </sec>
              <sec id="H2-12-ZOI230235">
                <title>Secondary Outcomes</title>
                <p>A total of 33 of 54 TAU participants (61.1%) and 60 of 77 C-OLP participants (77.9%) remained in treatment at 90 days (χ<sup>2</sup><sub>1</sub> = 4.356; <italic>P</italic> = .04), reflecting greater retention for C-OLP participants; the number needed to treat for the beneficial outcome of 3-month treatment retention, 6 (95% CI, 4-119) (<xref rid="zoi230235f3" ref-type="fig">Figure 3</xref>).</p>
                <fig position="float" id="zoi230235f3" fig-type="figure">
                  <label>Figure 3. </label>
                  <caption>
                    <title>Probability of Treatment Retention by Group</title>
                    <p>Estimated by the Kaplan-Meier method overall probability function. C-OLP (n = 77) overall probability, 0.75 (95% CI, 0.66-0.86); TAU (n = 54) overall probability, 0.59 (95% CI, 0.48-0.74). C-OLP indicates conditioned open-label placebo; TAU, treatment as usual.</p>
                  </caption>
                  <graphic xlink:href="jamanetwopen-e237099-g003" position="float"/>
                </fig>
                <p>Mixed-effects models showed that group C-OLP reported better sleep quality (global C-OLP PSQI score, 8.12 [0.48] vs 9.9 [0.46] for TAU; <italic>P</italic> = .047), an estimated mean PSQI score difference of 1.79 points. No statistically significant differences were found in any other outcome measure (eTable in <xref rid="note-ZOI230235-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p>
              </sec>
            </sec>
            <sec id="H1-4-ZOI230235">
              <title>Discussion</title>
              <p>Our primary aim was to test whether a C-OLP intervention could improve methadone treatment outcomes. Our hypothesis that 90-day methadone doses would be lower for C-OLP than for TAU recipients was not supported. We can only speculate as to why there were no significant differences between the groups, but due to its bioavailability, clearance, and half-life, methadone dosing is highly individualized.<sup><xref rid="zoi230235r47" ref-type="bibr">47</xref></sup> Furthermore, to avoid the risk of overdose, a patient’s methadone dose is affected by missed days, which can result in dose cuts or the need for reassessment and reinitiation. These influences may have precluded the ability to observe any potential group differences in methadone dose.</p>
              <p>Unexpectedly, we found a significant difference in the groups’ 90-day retention rates, with 61.1% retention attrition in the TAU group and 77.9% for group C-OLP (<xref rid="zoi230235f3" ref-type="fig">Figure 3</xref>). The observed TAU attrition rate is very similar to the 40% attrition reported in the comparison cohort of a recently published trial conducted at the same opioid treatment program,<sup><xref rid="zoi230235r56" ref-type="bibr">56</xref></sup> reinforcing the reliability of our TAU retention findings.</p>
              <p>Additionally, secondary analyses suggested another benefit in the C-OLP group: relative to the TAU participants, they reported better sleep over the first 90 days of treatment, with an estimated mean PSQI score difference of 1.78 points (<xref rid="zoi230235t2" ref-type="table">Table 2</xref>). Differences greater than 3 on the PSQI are generally considered clinically meaningful; however, 2 separate systematic reviews have identified differences between 1.54 and 3 as clinically meaningful.<sup><xref rid="zoi230235r57" ref-type="bibr">57</xref>,<xref rid="zoi230235r58" ref-type="bibr">58</xref></sup> Disrupted sleep can be a major challenge for patients with OUD,<sup><xref rid="zoi230235r59" ref-type="bibr">59</xref>,<xref rid="zoi230235r60" ref-type="bibr">60</xref></sup> and several trials are focusing on sleep as a therapeutic target for OUD (eg, <ext-link xlink:href="https://clinicaltrials.gov/ct2/show/NCT04287062" ext-link-type="uri">NCT04287062</ext-link>). Sleep itself may have large placebo effects that can be manipulated by conditioning paradigms.<sup><xref rid="zoi230235r39" ref-type="bibr">39</xref>,<xref rid="zoi230235r61" ref-type="bibr">61</xref></sup> Thus, our findings are consistent with prior research and suggest that studies should incorporate more detailed examinations of sleep as a mechanism of OUD treatment-related changes.</p>
              <table-wrap position="float" id="zoi230235t2">
                <label>Table 2. </label>
                <caption>
                  <title>Estimated Mean of Secondary Outcomes With Mixed Effects Longitudinal Regression Estimates in the TAU (n = 54) and C-OLP (n = 77) Groups</title>
                </caption>
                <table frame="hsides" rules="groups">
                  <col width="17.52%" span="1"/>
                  <col width="16.67%" span="1"/>
                  <col width="10.53%" span="1"/>
                  <col width="14.92%" span="1"/>
                  <col width="14.92%" span="1"/>
                  <col width="16.67%" span="1"/>
                  <col width="8.77%" span="1"/>
                  <thead>
                    <tr>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Domain</th>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Variable</th>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Group</th>
                      <th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Months after baseline estimate, mean (SE)</th>
                      <th rowspan="2" valign="top" align="left" scope="col" colspan="1">Global <italic>P</italic> value</th>
                    </tr>
                    <tr>
                      <th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">1</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">2</th>
                      <th valign="top" align="left" scope="col" rowspan="1" colspan="1">3</th>
                    </tr>
                  </thead>
                  <tbody>
                    <tr>
                      <td rowspan="10" valign="top" align="left" scope="row" colspan="1">Self-reported past 2-wk drug use, d</td>
                      <td rowspan="2" valign="top" align="left" colspan="1">Opiates</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.80 (0.66)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.86 (0.74)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">5.75 (0.75)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.46</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.96 (0.74)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.69 (0.55)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">4.45 (0.56)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" colspan="1" align="left" scope="row">Cocaine</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.28 (0.70)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">3.47 (0.77)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.36 (0.78)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.62</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.42 (0.57)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.65 (0.59)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.93 (0.60)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" colspan="1" align="left" scope="row">Benzodiazepines</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.57 (0.38)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.46 (0.41)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.73 (0.42)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.79</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.19 (0.31)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.28 (0.32)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.31 (0.32)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" colspan="1" align="left" scope="row">Alcohol</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.48 (0.36)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.61 (0.40)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.33 (0.40)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.94</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.29)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.87 (0.30)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">0.54 (0.30)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" colspan="1" align="left" scope="row">Other drug use</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.54 (0.52)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.05 (0.55)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.58 (0.56)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.44</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.17 (0.45)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.87 (0.46)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">2.12 (0.46)</td>
                    </tr>
                    <tr>
                      <td rowspan="4" valign="top" align="left" scope="row" colspan="1">Withdrawal</td>
                      <td rowspan="2" valign="top" align="left" colspan="1">Objective opiate withdrawal</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.72 (0.22)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.76 (0.24)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.45 (0.25)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.21</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.46 (0.17)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.21 (0.18)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">1.08 (0.18)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" colspan="1" align="left" scope="row">Subjective opiate withdrawal</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">17.2 (2.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">17.5 (2.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14.0 (2.6)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.19</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">14.6 (1.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">11.4 (1.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.4 (2.0)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Craving</td>
                      <td rowspan="2" valign="top" align="left" colspan="1">Adapted craving score</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.69 (1.06)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.36 (1.18)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8.68 (1.20)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.06</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6.84 (0.85)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6.61 (0.89)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">6.45 (0.90)</td>
                    </tr>
                    <tr>
                      <td rowspan="8" valign="top" align="left" scope="row" colspan="1">Quality of life: WHOQOL-BREF<xref rid="zoi230235t2n1" ref-type="table-fn"><sup>a</sup></xref></td>
                      <td rowspan="2" valign="top" align="left" colspan="1">Physiological health score domain</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">53.2 (2.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">51.5 (2.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">54.9 (2.3)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.82</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">52.0 (1.7)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">53.1 (1.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">54.0 (1.8)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" colspan="1" align="left" scope="row">Psychological health score domain</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">62.1 (2.3)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">60.6 (2.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">62.5 (2.6)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.99</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">61.8 (1.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">59.9 (2.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">62.2 (2.0)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" colspan="1" align="left" scope="row">Social relationships score domain</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">56.1 (3.5)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">62.2 (3.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">65.4 (3.9)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.13</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">64.8 (2.9)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">65.1 (3.0)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">64.1 (3.0)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" colspan="1" align="left" scope="row">Environment score domain</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">58.4 (2.6)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">56.4 (2.8)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">59.9 (2.2)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.89</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">57.9 (2.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">58.1 (2.2)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">59.1 (2.3)</td>
                    </tr>
                    <tr>
                      <td rowspan="2" valign="top" align="left" scope="row" colspan="1">Sleep</td>
                      <td rowspan="2" valign="top" align="left" colspan="1">Sleep: global PSQI score<xref rid="zoi230235t2n2" ref-type="table-fn"><sup>b</sup></xref></td>
                      <td valign="top" align="left" rowspan="1" colspan="1">TAU</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.92 (0.56)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.90 (0.46)</td>
                      <td rowspan="2" valign="middle" align="left" colspan="1">.047</td>
                    </tr>
                    <tr>
                      <td valign="top" colspan="1" align="left" scope="row" rowspan="1">C-OLP</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">9.04 (0.46)</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">NA</td>
                      <td valign="top" align="left" rowspan="1" colspan="1">8.12 (0.48)</td>
                    </tr>
                  </tbody>
                </table>
                <table-wrap-foot>
                  <p>Abbreviations: C-OLP, conditioned open-label placebo; NA, not applicable; PSQI, Pittsburgh Sleep Quality Index; TAU, treatment as usual; WHOQOL-BREF, World Health Organization Quality of Life assessment.</p>
                  <fn id="zoi230235t2n1">
                    <label>
                      <sup>a</sup>
                    </label>
                    <p>Scores range from 0 to 100, with higher scores indicating higher quality of life.</p>
                  </fn>
                  <fn id="zoi230235t2n2">
                    <label>
                      <sup>b</sup>
                    </label>
                    <p>Scores range from 0 to 21, with higher scores indicating worse quality of sleep.</p>
                  </fn>
                </table-wrap-foot>
              </table-wrap>
              <p>Our unique implementation combined 2 methods to harness placebo effects: OLP and pharmacologic conditioning. In open-label studies, no pretense is made concerning the fact that the pill or device is physiologically inert. Patient participants are oriented transparently to the possible beneficial effects of placebos. We did not guide participant expectations regarding our specific study aims; rather, participants were informed of the nonspecific therapeutic benefits that can accompany placebo therapy but were not informed of the operationalization of assessments.</p>
              <p>Few studies have combined conditioning and OLP. In a novel small feasibility study, Morales-Quezada and colleagues<sup><xref rid="zoi230235r36" ref-type="bibr">36</xref></sup> randomized inpatients with spinal cord injury to either C-OLP or TAU and compared subsequent opioid consumption rates and self-reported pain. The C-OLP group showed less opioid consumption and less pain relative to TAU. Flowers et al<sup><xref rid="zoi230235r37" ref-type="bibr">37</xref></sup> advanced these findings to conduct a larger RCT in patients following back surgery (again, the primary outcome was opioid consumption), and similarly found that patients receiving C-OLP consumed 30% less opioids for postoperative pain (−14.5 daily morphine milligram equivalents; 95% CI, −26.8 to −2.2 daily morphine milligram equivalents) and reported lower daily worst-pain scores (21.0 points; 95% CI, −2.0 to −0.1 points) than patients receiving TAU.<sup><xref rid="zoi230235r37" ref-type="bibr">37</xref></sup> These findings underscore the relevance of C-OLP in opioid paradigms.</p>
              <p>Although our results do not speak to mechanism, the beneficial effect of C-OLP on methadone treatment retention could be related to the benefits observed in sleep quality or other not-yet-assessed effects on overall function. As part of this RCT, we also obtained qualitative data from C-OLP participants to understand perceptions of efficacy—data that could help elucidate perceived benefits of C-OLP. A forthcoming study will represent these data in full.</p>
              <p>The clinical implications of the C-OLP intervention described in this study are great. Retention in treatment is a serious challenge for the field of addiction medicine and calls abound for an all hands on deck approach to identify solutions to stave overdose rates and increase treatment engagement and retention. We have demonstrated the general feasibility of administering a placebo adjunct to standard-of-care methadone in a community-based opioid treatment setting. Our experience running this trial showed us that C-OLP did not produce a significant burden to clinic procedures. Future studies should rigorously evaluate implementation outcomes, however (eg, patient and staff acceptability, measures of feasibility), to better inform the practicality of implementing a placebo adjunct to methadone treatment. Notwithstanding, the low-cost, low-risk nature of this intervention suggests that C-OLP could provide an appealing strategy to target early methadone treatment adherence. Well-powered studies are needed to evaluate this intervention’s efficacy on methadone treatment retention.</p>
              <sec id="H2-13-ZOI230235">
                <title>Strengths and Limitations</title>
                <p>Strengths of our study include the use of between-group structural equivalence and blind assessment. Furthermore, outcomes of interest (methadone doses and number of treatment days) were based on objective measures, extracted from patient records.</p>
                <p>This trial has limitations. It was not powered to detect group differences for outcomes other than methadone dose; secondary outcome differences could be artifactual. Additionally, open-label interventions are inherently incompatible with double-blinding. Previous open-label RCTs have been only assessor blinded; ours is one of the few in which the blind extended to the clinicians. Personal communications between the lead author (A.M.B.) and these individuals (treatment physicians [A.D.G., E.W.] and the nurse practitioner) suggest that this blind was not broken (ie, clinicians were not even aware of their patients’ study involvement). Despite this, the possibility still exists that C-OLP participants discussed the study with treatment team members. Furthermore, this study was conducted in a single setting—findings from which may not be generalizable to other treatment settings and populations. A planned larger trial will address this shortcoming. A final limitation is that we did not quite achieve our intended sample size of 60 participants in the TAU group.</p>
              </sec>
            </sec>
            <sec id="H1-5-ZOI230235">
              <title>Conclusions</title>
              <p>To our knowledge, this is the first RCT to assess the efficacy of a harnessed placebo intervention in a clinical OUD treatment context. Our findings of C-OLP–enhanced treatment retention and ameliorated sleep merit further investigation, especially considering the unchecked OUD epidemic that continues in the US.</p>
            </sec>
          </body>
          <back>
            <ref-list id="REF-ZOI230235">
              <title>References</title>
              <ref id="zoi230235r1">
                <label>1</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Volkow</surname><given-names>ND</given-names></string-name>, <string-name><surname>Frieden</surname><given-names>TR</given-names></string-name>, <string-name><surname>Hyde</surname><given-names>PS</given-names></string-name>, <string-name><surname>Cha</surname><given-names>SS</given-names></string-name></person-group>. <article-title>Medication-assisted therapies—tackling the opioid-overdose epidemic</article-title>. <source>N Engl J Med</source>. <year>2014</year>;<volume>370</volume>(<issue>22</issue>):<fpage>2063</fpage>-<lpage>2066</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMp1402780</pub-id><?supplied-pmid 24758595?><pub-id pub-id-type="pmid">24758595</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r2">
                <label>2</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dole</surname><given-names>VP</given-names></string-name>, <string-name><surname>Nyswander</surname><given-names>M</given-names></string-name></person-group>. <article-title>A medical treatment for diacetylmorphine (heroin) addiction: a clinical trial with methadone hydrochloride</article-title>. <source>JAMA</source>. <year>1965</year>;<volume>193</volume>(<issue>8</issue>):<fpage>646</fpage>-<lpage>650</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.1965.03090080008002</pub-id><?supplied-pmid 14321530?><pub-id pub-id-type="pmid">14321530</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r3">
                <label>3</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mattick</surname><given-names>RP</given-names></string-name>, <string-name><surname>Breen</surname><given-names>C</given-names></string-name>, <string-name><surname>Kimber</surname><given-names>J</given-names></string-name>, <string-name><surname>Davoli</surname><given-names>M</given-names></string-name></person-group>. <article-title>Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2009</year>;<volume>2009</volume>(<issue>3</issue>):<elocation-id>CD002209</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD002209.pub2</pub-id><?supplied-pmid 19588333?><pub-id pub-id-type="pmid">19588333</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r4">
                <label>4</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Mattick</surname><given-names>RP</given-names></string-name>, <string-name><surname>Breen</surname><given-names>C</given-names></string-name>, <string-name><surname>Kimber</surname><given-names>J</given-names></string-name>, <string-name><surname>Davoli</surname><given-names>M</given-names></string-name></person-group>. <article-title>Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence</article-title>. <source>Cochrane Database Syst Rev</source>. <year>2014</year>;(<issue>2</issue>):<elocation-id>CD002207</elocation-id>. doi:<pub-id pub-id-type="doi">10.1002/14651858.CD002207.pub4</pub-id><?supplied-pmid 24500948?><pub-id pub-id-type="pmid">24500948</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r5">
                <label>5</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Martin</surname><given-names>JA</given-names></string-name>, <string-name><surname>Campbell</surname><given-names>A</given-names></string-name>, <string-name><surname>Killip</surname><given-names>T</given-names></string-name>, <etal/>; <collab>Substance Abuse and Mental Health Services Administration</collab></person-group>. <article-title>QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel</article-title>. <source>J Addict Dis</source>. <year>2011</year>;<volume>30</volume>(<issue>4</issue>):<fpage>283</fpage>-<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.1080/10550887.2011.610710</pub-id><?supplied-pmid 22026519?><pub-id pub-id-type="pmid">22026519</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r6">
                <label>6</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kaptchuk</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Miller</surname><given-names>FG</given-names></string-name></person-group>. <article-title>Placebo effects in medicine</article-title>. <source>N Engl J Med</source>. <year>2015</year>;<volume>373</volume>(<issue>1</issue>):<fpage>8</fpage>-<lpage>9</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMp1504023</pub-id><?supplied-pmid 26132938?><pub-id pub-id-type="pmid">26132938</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r7">
                <label>7</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Belcher</surname><given-names>AM</given-names></string-name>, <string-name><surname>Ferré</surname><given-names>S</given-names></string-name>, <string-name><surname>Martinez</surname><given-names>PE</given-names></string-name>, <string-name><surname>Colloca</surname><given-names>L</given-names></string-name></person-group>. <article-title>Role of placebo effects in pain and neuropsychiatric disorders</article-title>. <source>Prog Neuropsychopharmacol Biol Psychiatry</source>. <year>2018</year>;<volume>87</volume>(<issue>Pt B</issue>):<fpage>298</fpage>-<lpage>306</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.06.003</pub-id><?supplied-pmid 28595945?><pub-id pub-id-type="pmid">28595945</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r8">
                <label>8</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kaptchuk</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Hemond</surname><given-names>CC</given-names></string-name>, <string-name><surname>Miller</surname><given-names>FG</given-names></string-name></person-group>. <article-title>Placebos in chronic pain: evidence, theory, ethics, and use in clinical practice</article-title>. <source>BMJ</source>. <year>2020</year>;<volume>370</volume>:<fpage>m1668</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.m1668</pub-id><?supplied-pmid 32690477?><pub-id pub-id-type="pmid">32690477</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r9">
                <label>9</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nicholas</surname><given-names>M</given-names></string-name>, <string-name><surname>Vlaeyen</surname><given-names>JWS</given-names></string-name>, <string-name><surname>Rief</surname><given-names>W</given-names></string-name>, <etal/>; <collab>IASP Taskforce for the Classification of Chronic Pain</collab></person-group>. <article-title>The IASP classification of chronic pain for <italic>ICD-11</italic>: chronic primary pain</article-title>. <source>Pain</source>. <year>2019</year>;<volume>160</volume>(<issue>1</issue>):<fpage>28</fpage>-<lpage>37</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000001390</pub-id><?supplied-pmid 30586068?><pub-id pub-id-type="pmid">30586068</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r10">
                <label>10</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Charlesworth</surname><given-names>JEG</given-names></string-name>, <string-name><surname>Petkovic</surname><given-names>G</given-names></string-name>, <string-name><surname>Kelley</surname><given-names>JM</given-names></string-name>, <etal/></person-group>. <article-title>Effects of placebos without deception compared with no treatment: a systematic review and meta-analysis</article-title>. <source>J Evid Based Med</source>. <year>2017</year>;<volume>10</volume>(<issue>2</issue>):<fpage>97</fpage>-<lpage>107</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jebm.12251</pub-id><?supplied-pmid 28452193?><pub-id pub-id-type="pmid">28452193</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r11">
                <label>11</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>von Wernsdorff</surname><given-names>M</given-names></string-name>, <string-name><surname>Loef</surname><given-names>M</given-names></string-name>, <string-name><surname>Tuschen-Caffier</surname><given-names>B</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>S</given-names></string-name></person-group>. <article-title>Effects of open-label placebos in clinical trials: a systematic review and meta-analysis</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>3855</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-021-83148-6</pub-id><?supplied-pmid 33594150?><pub-id pub-id-type="pmid">33594150</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r12">
                <label>12</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kaptchuk</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Friedlander</surname><given-names>E</given-names></string-name>, <string-name><surname>Kelley</surname><given-names>JM</given-names></string-name>, <etal/></person-group>. <article-title>Placebos without deception: a randomized controlled trial in irritable bowel syndrome</article-title>. <source>PLoS One</source>. <year>2010</year>;<volume>5</volume>(<issue>12</issue>):<elocation-id>e15591</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0015591</pub-id><?supplied-pmid 21203519?><pub-id pub-id-type="pmid">21203519</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r13">
                <label>13</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Lembo</surname><given-names>A</given-names></string-name>, <string-name><surname>Kelley</surname><given-names>JM</given-names></string-name>, <string-name><surname>Nee</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Open-label placebo vs double-blind placebo for irritable bowel syndrome: a randomized clinical trial</article-title>. <source>Pain</source>. <year>2021</year>;<volume>162</volume>(<issue>9</issue>):<fpage>2428</fpage>-<lpage>2435</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000002234</pub-id><?supplied-pmid 33605656?><pub-id pub-id-type="pmid">33605656</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r14">
                <label>14</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Nurko</surname><given-names>S</given-names></string-name>, <string-name><surname>Saps</surname><given-names>M</given-names></string-name>, <string-name><surname>Kossowsky</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Effect of open-label placebo on children and adolescents with functional abdominal pain or irritable bowel syndrome: a randomized clinical trial</article-title>. <source>JAMA Pediatr</source>. <year>2022</year>;<volume>176</volume>(<issue>4</issue>):<fpage>349</fpage>-<lpage>356</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamapediatrics.2021.5750</pub-id><?supplied-pmid 35099543?><pub-id pub-id-type="pmid">35099543</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r15">
                <label>15</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Carvalho</surname><given-names>C</given-names></string-name>, <string-name><surname>Caetano</surname><given-names>JM</given-names></string-name>, <string-name><surname>Cunha</surname><given-names>L</given-names></string-name>, <string-name><surname>Rebouta</surname><given-names>P</given-names></string-name>, <string-name><surname>Kaptchuk</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Kirsch</surname><given-names>I</given-names></string-name></person-group>. <article-title>Open-label placebo treatment in chronic low back pain: a randomized controlled trial</article-title>. <source>Pain</source>. <year>2016</year>;<volume>157</volume>(<issue>12</issue>):<fpage>2766</fpage>-<lpage>2772</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000000700</pub-id><?supplied-pmid 27755279?><pub-id pub-id-type="pmid">27755279</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r16">
                <label>16</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Olliges</surname><given-names>E</given-names></string-name>, <string-name><surname>Stroppe</surname><given-names>S</given-names></string-name>, <string-name><surname>Haile</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Open-label placebo administration decreases pain in elderly patients with symptomatic knee osteoarthritis - a randomized controlled trial</article-title>. <source>Front Psychiatry</source>. <year>2022</year>;<volume>13</volume>:<elocation-id>853497</elocation-id>. doi:<pub-id pub-id-type="doi">10.3389/fpsyt.2022.853497</pub-id><?supplied-pmid 35599777?><pub-id pub-id-type="pmid">35599777</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r17">
                <label>17</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kleine-Borgmann</surname><given-names>J</given-names></string-name>, <string-name><surname>Schmidt</surname><given-names>K</given-names></string-name>, <string-name><surname>Hellmann</surname><given-names>A</given-names></string-name>, <string-name><surname>Bingel</surname><given-names>U</given-names></string-name></person-group>. <article-title>Effects of open-label placebo on pain, functional disability, and spine mobility in patients with chronic back pain: a randomized controlled trial</article-title>. <source>Pain</source>. <year>2019</year>;<volume>160</volume>(<issue>12</issue>):<fpage>2891</fpage>-<lpage>2897</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000001683</pub-id><?supplied-pmid 31479068?><pub-id pub-id-type="pmid">31479068</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r18">
                <label>18</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Carvalho</surname><given-names>C</given-names></string-name>, <string-name><surname>Pais</surname><given-names>M</given-names></string-name>, <string-name><surname>Cunha</surname><given-names>L</given-names></string-name>, <string-name><surname>Rebouta</surname><given-names>P</given-names></string-name>, <string-name><surname>Kaptchuk</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Kirsch</surname><given-names>I</given-names></string-name></person-group>. <article-title>Open-label placebo for chronic low back pain: a 5-year follow-up</article-title>. <source>Pain</source>. <year>2021</year>;<volume>162</volume>(<issue>5</issue>):<fpage>1521</fpage>-<lpage>1527</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000002162</pub-id><?supplied-pmid 33259459?><pub-id pub-id-type="pmid">33259459</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r19">
                <label>19</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Schaefer</surname><given-names>M</given-names></string-name>, <string-name><surname>Harke</surname><given-names>R</given-names></string-name>, <string-name><surname>Denke</surname><given-names>C</given-names></string-name></person-group>. <article-title>Open-label placebos improve symptoms in allergic rhinitis: a randomized controlled trial</article-title>. <source>Psychother Psychosom</source>. <year>2016</year>;<volume>85</volume>(<issue>6</issue>):<fpage>373</fpage>-<lpage>374</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000447242</pub-id><?supplied-pmid 27744433?><pub-id pub-id-type="pmid">27744433</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r20">
                <label>20</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Schaefer</surname><given-names>M</given-names></string-name>, <string-name><surname>Sahin</surname><given-names>T</given-names></string-name>, <string-name><surname>Berstecher</surname><given-names>B</given-names></string-name></person-group>. <article-title>Why do open-label placebos work? a randomized controlled trial of an open-label placebo induction with and without extended information about the placebo effect in allergic rhinitis</article-title>. <source>PLoS One</source>. <year>2018</year>;<volume>13</volume>(<issue>3</issue>):<elocation-id>e0192758</elocation-id>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0192758</pub-id><?supplied-pmid 29513699?><pub-id pub-id-type="pmid">29513699</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r21">
                <label>21</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kam-Hansen</surname><given-names>S</given-names></string-name>, <string-name><surname>Jakubowski</surname><given-names>M</given-names></string-name>, <string-name><surname>Kelley</surname><given-names>JM</given-names></string-name>, <etal/></person-group>. <article-title>Altered placebo and drug labeling changes the outcome of episodic migraine attacks</article-title>. <source>Sci Transl Med</source>. <year>2014</year>;<volume>6</volume>(<issue>218</issue>):<elocation-id>218ra5</elocation-id>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.3006175</pub-id><?supplied-pmid 24401940?><pub-id pub-id-type="pmid">24401940</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r22">
                <label>22</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Zhou</surname><given-names>ES</given-names></string-name>, <string-name><surname>Hall</surname><given-names>KT</given-names></string-name>, <string-name><surname>Michaud</surname><given-names>AL</given-names></string-name>, <string-name><surname>Blackmon</surname><given-names>JE</given-names></string-name>, <string-name><surname>Partridge</surname><given-names>AH</given-names></string-name>, <string-name><surname>Recklitis</surname><given-names>CJ</given-names></string-name></person-group>. <article-title>Open-label placebo reduces fatigue in cancer survivors: a randomized trial</article-title>. <source>Support Care Cancer</source>. <year>2019</year>;<volume>27</volume>(<issue>6</issue>):<fpage>2179</fpage>-<lpage>2187</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00520-018-4477-6</pub-id><?supplied-pmid 30298411?><pub-id pub-id-type="pmid">30298411</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r23">
                <label>23</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Hoenemeyer</surname><given-names>TW</given-names></string-name>, <string-name><surname>Kaptchuk</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Mehta</surname><given-names>TS</given-names></string-name>, <string-name><surname>Fontaine</surname><given-names>KR</given-names></string-name></person-group>. <article-title>Open-label placebo treatment for cancer-related fatigue: a randomized-controlled clinical trial</article-title>. <source>Sci Rep</source>. <year>2018</year>;<volume>8</volume>(<issue>1</issue>):<fpage>2784</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-018-20993-y</pub-id><?supplied-pmid 29426869?><pub-id pub-id-type="pmid">29426869</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r24">
                <label>24</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pan</surname><given-names>Y</given-names></string-name>, <string-name><surname>Meister</surname><given-names>R</given-names></string-name>, <string-name><surname>Löwe</surname><given-names>B</given-names></string-name>, <string-name><surname>Kaptchuk</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Buhling</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Nestoriuc</surname><given-names>Y</given-names></string-name></person-group>. <article-title>Open-label placebos for menopausal hot flushes: a randomized controlled trial</article-title>. <source>Sci Rep</source>. <year>2020</year>;<volume>10</volume>(<issue>1</issue>):<fpage>20090</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41598-020-77255-z</pub-id><?supplied-pmid 33208855?><pub-id pub-id-type="pmid">33208855</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r25">
                <label>25</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kaptchuk</surname><given-names>TJ</given-names></string-name>, <string-name><surname>Miller</surname><given-names>FG</given-names></string-name></person-group>. <article-title>Open label placebo: can honestly prescribed placebos evoke meaningful therapeutic benefits?</article-title><source>BMJ</source>. <year>2018</year>;<volume>363</volume>:<fpage>k3889</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.k3889</pub-id><?supplied-pmid 30279235?><pub-id pub-id-type="pmid">30279235</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r26">
                <label>26</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Amanzio</surname><given-names>M</given-names></string-name>, <string-name><surname>Benedetti</surname><given-names>F</given-names></string-name></person-group>. <article-title>Neuropharmacological dissection of placebo analgesia: expectation-activated opioid systems versus conditioning-activated specific subsystems</article-title>. <source>J Neurosci</source>. <year>1999</year>;<volume>19</volume>(<issue>1</issue>):<fpage>484</fpage>-<lpage>494</lpage>. doi:<pub-id pub-id-type="doi">10.1523/JNEUROSCI.19-01-00484.1999</pub-id><?supplied-pmid 9870976?><pub-id pub-id-type="pmid">9870976</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r27">
                <label>27</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Benedetti</surname><given-names>F</given-names></string-name>, <string-name><surname>Pollo</surname><given-names>A</given-names></string-name>, <string-name><surname>Lopiano</surname><given-names>L</given-names></string-name>, <string-name><surname>Lanotte</surname><given-names>M</given-names></string-name>, <string-name><surname>Vighetti</surname><given-names>S</given-names></string-name>, <string-name><surname>Rainero</surname><given-names>I</given-names></string-name></person-group>. <article-title>Conscious expectation and unconscious conditioning in analgesic, motor, and hormonal placebo/nocebo responses</article-title>. <source>J Neurosci</source>. <year>2003</year>;<volume>23</volume>(<issue>10</issue>):<fpage>4315</fpage>-<lpage>4323</lpage>. doi:<pub-id pub-id-type="doi">10.1523/JNEUROSCI.23-10-04315.2003</pub-id><?supplied-pmid 12764120?><pub-id pub-id-type="pmid">12764120</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r28">
                <label>28</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Colloca</surname><given-names>L</given-names></string-name>, <string-name><surname>Enck</surname><given-names>P</given-names></string-name>, <string-name><surname>DeGrazia</surname><given-names>D</given-names></string-name></person-group>. <article-title>Relieving pain using dose-extending placebos: a scoping review</article-title>. <source>Pain</source>. <year>2016</year>;<volume>157</volume>(<issue>8</issue>):<fpage>1590</fpage>-<lpage>1598</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000000566</pub-id><?supplied-pmid 27023425?><pub-id pub-id-type="pmid">27023425</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r29">
                <label>29</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Pavlov</surname><given-names>PI</given-names></string-name></person-group>. <article-title>Conditioned reflexes: an investigation of the physiological activity of the cerebral cortex</article-title>. <source>Ann Neurosci</source>. <year>2010</year>;<volume>17</volume>(<issue>3</issue>):<fpage>136</fpage>-<lpage>141</lpage>. doi:<pub-id pub-id-type="doi">10.5214/ans.0972-7531.1017309</pub-id><?supplied-pmid 25205891?><pub-id pub-id-type="pmid">25205891</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r30">
                <label>30</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Herrnstein</surname><given-names>RJ</given-names></string-name></person-group>. <article-title>Placebo effect in the rat</article-title>. <source>Science</source>. <year>1962</year>;<volume>138</volume>(<issue>3541</issue>):<fpage>677</fpage>-<lpage>678</lpage>. doi:<pub-id pub-id-type="doi">10.1126/science.138.3541.677</pub-id><?supplied-pmid 13954106?><pub-id pub-id-type="pmid">13954106</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r31">
                <label>31</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ader</surname><given-names>R</given-names></string-name></person-group>. <article-title>Letter: Behaviorially conditioned immunosuppression</article-title>. <source>Psychosom Med</source>. <year>1974</year>;<volume>36</volume>(<issue>2</issue>):<fpage>183</fpage>-<lpage>184</lpage>. doi:<pub-id pub-id-type="doi">10.1097/00006842-197403000-00011</pub-id><?supplied-pmid 4814671?><pub-id pub-id-type="pmid">4814671</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r32">
                <label>32</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ader</surname><given-names>R</given-names></string-name>, <string-name><surname>Cohen</surname><given-names>N</given-names></string-name></person-group>. <article-title>Conditioning of the immune response</article-title>. <source>Neth J Med</source>. <year>1991</year>;<volume>39</volume>(<issue>3-4</issue>):<fpage>263</fpage>-<lpage>273</lpage>.<?supplied-pmid 1791889?><pub-id pub-id-type="pmid">1791889</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r33">
                <label>33</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sandler</surname><given-names>AD</given-names></string-name>, <string-name><surname>Bodfish</surname><given-names>JW</given-names></string-name></person-group>. <article-title>Open-label use of placebos in the treatment of ADHD: a pilot study</article-title>. <source>Child Care Health Dev</source>. <year>2008</year>;<volume>34</volume>(<issue>1</issue>):<fpage>104</fpage>-<lpage>110</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2214.2007.00797.x</pub-id><?supplied-pmid 18171451?><pub-id pub-id-type="pmid">18171451</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r34">
                <label>34</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Sandler</surname><given-names>AD</given-names></string-name>, <string-name><surname>Glesne</surname><given-names>CE</given-names></string-name>, <string-name><surname>Bodfish</surname><given-names>JW</given-names></string-name></person-group>. <article-title>Conditioned placebo dose reduction: a new treatment in attention-deficit hyperactivity disorder?</article-title><source>J Dev Behav Pediatr JDBP.</source><year>2010</year>;<volume>31</volume>(<issue>5</issue>):<fpage>369</fpage>-<lpage>375</lpage>. doi:<pub-id pub-id-type="doi">10.1097/DBP.0b013e3181e121ed</pub-id><?supplied-pmid 20495473?><pub-id pub-id-type="pmid">20495473</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r35">
                <label>35</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Bernstein</surname><given-names>MH</given-names></string-name>, <string-name><surname>Magill</surname><given-names>M</given-names></string-name>, <string-name><surname>Weiss</surname><given-names>AP</given-names></string-name>, <etal/></person-group>. <article-title>Are conditioned open placebos feasible as an adjunctive treatment to opioids? results from a single-group dose-extender pilot study with acute pain patients</article-title>. <source>Psychother Psychosom</source>. <year>2019</year>;<volume>88</volume>(<issue>6</issue>):<fpage>380</fpage>-<lpage>382</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000503038</pub-id><?supplied-pmid 31563914?><pub-id pub-id-type="pmid">31563914</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r36">
                <label>36</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Morales-Quezada</surname><given-names>L</given-names></string-name>, <string-name><surname>Mesia-Toledo</surname><given-names>I</given-names></string-name>, <string-name><surname>Estudillo-Guerra</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Conditioning open-label placebo: a pilot pharmacobehavioral approach for opioid dose reduction and pain control</article-title>. <source>Pain Rep</source>. <year>2020</year>;<volume>5</volume>(<issue>4</issue>):<elocation-id>e828</elocation-id>. doi:<pub-id pub-id-type="doi">10.1097/PR9.0000000000000828</pub-id><?supplied-pmid 32766465?><pub-id pub-id-type="pmid">32766465</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r37">
                <label>37</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Flowers</surname><given-names>KM</given-names></string-name>, <string-name><surname>Patton</surname><given-names>ME</given-names></string-name>, <string-name><surname>Hruschak</surname><given-names>VJ</given-names></string-name>, <etal/></person-group>. <article-title>Conditioned open-label placebo for opioid reduction after spine surgery: a randomized controlled trial</article-title>. <source>Pain</source>. <year>2021</year>;<volume>162</volume>(<issue>6</issue>):<fpage>1828</fpage>-<lpage>1839</lpage>. doi:<pub-id pub-id-type="doi">10.1097/j.pain.0000000000002185</pub-id><?supplied-pmid 33449503?><pub-id pub-id-type="pmid">33449503</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r38">
                <label>38</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Ader</surname><given-names>R</given-names></string-name>, <string-name><surname>Mercurio</surname><given-names>MG</given-names></string-name>, <string-name><surname>Walton</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Conditioned pharmacotherapeutic effects: a preliminary study</article-title>. <source>Psychosom Med</source>. <year>2010</year>;<volume>72</volume>(<issue>2</issue>):<fpage>192</fpage>-<lpage>197</lpage>. doi:<pub-id pub-id-type="doi">10.1097/PSY.0b013e3181cbd38b</pub-id><?supplied-pmid 20028830?><pub-id pub-id-type="pmid">20028830</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r39">
                <label>39</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Perlis</surname><given-names>M</given-names></string-name>, <string-name><surname>Grandner</surname><given-names>M</given-names></string-name>, <string-name><surname>Zee</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Durability of treatment response to zolpidem with three different maintenance regimens: a preliminary study</article-title>. <source>Sleep Med</source>. <year>2015</year>;<volume>16</volume>(<issue>9</issue>):<fpage>1160</fpage>-<lpage>1168</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2015.06.015</pub-id><?supplied-pmid 26298795?><pub-id pub-id-type="pmid">26298795</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r40">
                <label>40</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Goebel</surname><given-names>MU</given-names></string-name>, <string-name><surname>Meykadeh</surname><given-names>N</given-names></string-name>, <string-name><surname>Kou</surname><given-names>W</given-names></string-name>, <string-name><surname>Schedlowski</surname><given-names>M</given-names></string-name>, <string-name><surname>Hengge</surname><given-names>UR</given-names></string-name></person-group>. <article-title>Behavioral conditioning of antihistamine effects in patients with allergic rhinitis</article-title>. <source>Psychother Psychosom</source>. <year>2008</year>;<volume>77</volume>(<issue>4</issue>):<fpage>227</fpage>-<lpage>234</lpage>. doi:<pub-id pub-id-type="doi">10.1159/000126074</pub-id><?supplied-pmid 18418029?><pub-id pub-id-type="pmid">18418029</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r41">
                <label>41</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kirchhof</surname><given-names>J</given-names></string-name>, <string-name><surname>Petrakova</surname><given-names>L</given-names></string-name>, <string-name><surname>Brinkhoff</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Learned immunosuppressive placebo responses in renal transplant patients</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2018</year>;<volume>115</volume>(<issue>16</issue>):<fpage>4223</fpage>-<lpage>4227</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1720548115</pub-id><?supplied-pmid 29610294?><pub-id pub-id-type="pmid">29610294</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r42">
                <label>42</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Belcher</surname><given-names>AM</given-names></string-name>, <string-name><surname>Cole</surname><given-names>TO</given-names></string-name>, <string-name><surname>Greenblatt</surname><given-names>AD</given-names></string-name>, <etal/></person-group>. <article-title>Open-label dose-extending placebos for opioid use disorder: a protocol for a randomised controlled clinical trial with methadone treatment</article-title>. <source>BMJ Open</source>. <year>2019</year>;<volume>9</volume>(<issue>6</issue>):<elocation-id>e026604</elocation-id>. doi:<pub-id pub-id-type="doi">10.1136/bmjopen-2018-026604</pub-id><?supplied-pmid 31230007?><pub-id pub-id-type="pmid">31230007</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r43">
                <label>43</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name><surname>Hopewell</surname><given-names>S</given-names></string-name>, <string-name><surname>Schulz</surname><given-names>KF</given-names></string-name>, <etal/></person-group>. <article-title>CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials</article-title>. <source>BMJ</source>. <year>2010</year>;<volume>340</volume>:<fpage>c869</fpage>. doi:<pub-id pub-id-type="doi">10.1136/bmj.c869</pub-id><?supplied-pmid 20332511?><pub-id pub-id-type="pmid">20332511</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r44">
                <label>44</label>
                <mixed-citation publication-type="book"><person-group><collab>American Psychiatric Association</collab></person-group>. <source>Diagnostic and Statistical Manual of Mental Disorders</source>. <edition>5th ed</edition>. <publisher-name>American Psychiatric Association</publisher-name>; <year>2013</year>.</mixed-citation>
              </ref>
              <ref id="zoi230235r45">
                <label>45</label>
                <mixed-citation publication-type="webpage"><person-group><collab>CBS New York</collab></person-group>. Seen at 11: prescription placebo. CBS New York. <year>2016</year>. Accessed March 14, 2019. <ext-link xlink:href="https://www.youtube.com/watch?v=Jp14Lhl0T9w" ext-link-type="uri">https://www.youtube.com/watch?v=Jp14Lhl0T9w</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230235r46">
                <label>46</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Colloca</surname><given-names>L</given-names></string-name>, <string-name><surname>Petrovic</surname><given-names>P</given-names></string-name>, <string-name><surname>Wager</surname><given-names>TD</given-names></string-name>, <string-name><surname>Ingvar</surname><given-names>M</given-names></string-name>, <string-name><surname>Benedetti</surname><given-names>F</given-names></string-name></person-group>. <article-title>How the number of learning trials affects placebo and nocebo responses</article-title>. <source>Pain</source>. <year>2010</year>;<volume>151</volume>(<issue>2</issue>):<fpage>430</fpage>-<lpage>439</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pain.2010.08.007</pub-id><?supplied-pmid 20817355?><pub-id pub-id-type="pmid">20817355</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r47">
                <label>47</label>
                <mixed-citation publication-type="webpage"><person-group><collab>Substance Abuse and Mental Health Services Administration (SAMHSA)</collab></person-group>. TIP 63: medications for opioid use disorder. 2021. Accessed March 7, 2023. <ext-link xlink:href="https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf" ext-link-type="uri">https://store.samhsa.gov/sites/default/files/pep21-02-01-002.pdf</ext-link></mixed-citation>
              </ref>
              <ref id="zoi230235r48">
                <label>48</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Simpson</surname><given-names>DD</given-names></string-name></person-group>. <article-title>Treatment for drug abuse: follow-up outcomes and length of time spent</article-title>. <source>Arch Gen Psychiatry</source>. <year>1981</year>;<volume>38</volume>(<issue>8</issue>):<fpage>875</fpage>-<lpage>880</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archpsyc.1981.01780330033003</pub-id><?supplied-pmid 7259424?><pub-id pub-id-type="pmid">7259424</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r49">
                <label>49</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Torrens</surname><given-names>M</given-names></string-name>, <string-name><surname>Castillo</surname><given-names>C</given-names></string-name>, <string-name><surname>Pérez-Solá</surname><given-names>V</given-names></string-name></person-group>. <article-title>Retention in a low-threshold methadone maintenance program</article-title>. <source>Drug Alcohol Depend</source>. <year>1996</year>;<volume>41</volume>(<issue>1</issue>):<fpage>55</fpage>-<lpage>59</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0376-8716(96)01230-6</pub-id><?supplied-pmid 8793310?><pub-id pub-id-type="pmid">8793310</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r50">
                <label>50</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Handelsman</surname><given-names>L</given-names></string-name>, <string-name><surname>Cochrane</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Aronson</surname><given-names>MJ</given-names></string-name>, <string-name><surname>Ness</surname><given-names>R</given-names></string-name>, <string-name><surname>Rubinstein</surname><given-names>KJ</given-names></string-name>, <string-name><surname>Kanof</surname><given-names>PD</given-names></string-name></person-group>. <article-title>Two new rating scales for opiate withdrawal</article-title>. <source>Am J Drug Alcohol Abuse</source>. <year>1987</year>;<volume>13</volume>(<issue>3</issue>):<fpage>293</fpage>-<lpage>308</lpage>. doi:<pub-id pub-id-type="doi">10.3109/00952998709001515</pub-id><?supplied-pmid 3687892?><pub-id pub-id-type="pmid">3687892</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r51">
                <label>51</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>MacKillop</surname><given-names>J</given-names></string-name>, <string-name><surname>Lisman</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Effects of a context shift and multiple context extinction on reactivity to alcohol cues</article-title>. <source>Exp Clin Psychopharmacol</source>. <year>2008</year>;<volume>16</volume>(<issue>4</issue>):<fpage>322</fpage>-<lpage>331</lpage>. doi:<pub-id pub-id-type="doi">10.1037/a0012686</pub-id><?supplied-pmid 18729687?><pub-id pub-id-type="pmid">18729687</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r52">
                <label>52</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jobes</surname><given-names>ML</given-names></string-name>, <string-name><surname>Aharonovich</surname><given-names>E</given-names></string-name>, <string-name><surname>Epstein</surname><given-names>DH</given-names></string-name>, <etal/></person-group>. <article-title>Effects of prereactivation propranolol on cocaine craving elicited by imagery script/cue sets in opioid-dependent polydrug users: a randomized study</article-title>. <source>J Addict Med</source>. <year>2015</year>;<volume>9</volume>(<issue>6</issue>):<fpage>491</fpage>-<lpage>498</lpage>. doi:<pub-id pub-id-type="doi">10.1097/ADM.0000000000000169</pub-id><?supplied-pmid 26501788?><pub-id pub-id-type="pmid">26501788</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r53">
                <label>53</label>
                <mixed-citation publication-type="journal"><person-group><collab>The WHOQOL Group</collab></person-group>. <article-title>Development of the World Health Organization WHOQOL-BREF quality of life assessment</article-title>. <source>Psychol Med</source>. <year>1998</year>;<volume>28</volume>(<issue>3</issue>):<fpage>551</fpage>-<lpage>558</lpage>. doi:<pub-id pub-id-type="doi">10.1017/S0033291798006667</pub-id><?supplied-pmid 9626712?><pub-id pub-id-type="pmid">9626712</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r54">
                <label>54</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Buysse</surname><given-names>DJ</given-names></string-name>, <string-name><surname>Reynolds</surname><given-names>CF</given-names><suffix>III</suffix></string-name>, <string-name><surname>Monk</surname><given-names>TH</given-names></string-name>, <string-name><surname>Berman</surname><given-names>SR</given-names></string-name>, <string-name><surname>Kupfer</surname><given-names>DJ</given-names></string-name></person-group>. <article-title>The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research</article-title>. <source>Psychiatry Res</source>. <year>1989</year>;<volume>28</volume>(<issue>2</issue>):<fpage>193</fpage>-<lpage>213</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0165-1781(89)90047-4</pub-id><?supplied-pmid 2748771?><pub-id pub-id-type="pmid">2748771</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r55">
                <label>55</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Harris</surname><given-names>PA</given-names></string-name>, <string-name><surname>Taylor</surname><given-names>R</given-names></string-name>, <string-name><surname>Thielke</surname><given-names>R</given-names></string-name>, <string-name><surname>Payne</surname><given-names>J</given-names></string-name>, <string-name><surname>Gonzalez</surname><given-names>N</given-names></string-name>, <string-name><surname>Conde</surname><given-names>JG</given-names></string-name></person-group>. <article-title>Research electronic data capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support</article-title>. <source>J Biomed Inform</source>. <year>2009</year>;<volume>42</volume>(<issue>2</issue>):<fpage>377</fpage>-<lpage>381</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jbi.2008.08.010</pub-id><?supplied-pmid 18929686?><pub-id pub-id-type="pmid">18929686</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r56">
                <label>56</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Magidson</surname><given-names>JF</given-names></string-name>, <string-name><surname>Kleinman</surname><given-names>MB</given-names></string-name>, <string-name><surname>Bradley</surname><given-names>V</given-names></string-name>, <etal/></person-group>. <article-title>Peer recovery specialist-delivered, behavioral activation intervention to improve retention in methadone treatment: results from an open-label, type 1 hybrid effectiveness-implementation pilot trial</article-title>. <source>Int J Drug Policy</source>. <year>2022</year>;<volume>108</volume>:<elocation-id>103813</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.drugpo.2022.103813</pub-id><?supplied-pmid 35932644?><pub-id pub-id-type="pmid">35932644</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r57">
                <label>57</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Kim</surname><given-names>SH</given-names></string-name>, <string-name><surname>Jeong</surname><given-names>JH</given-names></string-name>, <string-name><surname>Lim</surname><given-names>JH</given-names></string-name>, <string-name><surname>Kim</surname><given-names>BK</given-names></string-name></person-group>. <article-title>Acupuncture using pattern-identification for the treatment of insomnia disorder: a systematic review and meta-analysis of randomized controlled trials</article-title>. <source>Integr Med Res</source>. <year>2019</year>;<volume>8</volume>(<issue>3</issue>):<fpage>216</fpage>-<lpage>226</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.imr.2019.08.002</pub-id><?supplied-pmid 31497504?><pub-id pub-id-type="pmid">31497504</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r58">
                <label>58</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Shergis</surname><given-names>JL</given-names></string-name>, <string-name><surname>Ni</surname><given-names>X</given-names></string-name>, <string-name><surname>Jackson</surname><given-names>ML</given-names></string-name>, <etal/></person-group>. <article-title>A systematic review of acupuncture for sleep quality in people with insomnia</article-title>. <source>Complement Ther Med</source>. <year>2016</year>;<volume>26</volume>:<fpage>11</fpage>-<lpage>20</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ctim.2016.02.007</pub-id><?supplied-pmid 27261976?><pub-id pub-id-type="pmid">27261976</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r59">
                <label>59</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Dunn</surname><given-names>KE</given-names></string-name>, <string-name><surname>Finan</surname><given-names>PH</given-names></string-name>, <string-name><surname>Andrew Tompkins</surname><given-names>D</given-names></string-name>, <string-name><surname>Strain</surname><given-names>EC</given-names></string-name></person-group>. <article-title>Frequency and correlates of sleep disturbance in methadone and buprenorphine-maintained patients</article-title>. <source>Addict Behav</source>. <year>2018</year>;<volume>76</volume>:<fpage>8</fpage>-<lpage>14</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.addbeh.2017.07.016</pub-id><?supplied-pmid 28735039?><pub-id pub-id-type="pmid">28735039</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r60">
                <label>60</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Baldassarri</surname><given-names>SR</given-names></string-name>, <string-name><surname>Beitel</surname><given-names>M</given-names></string-name>, <string-name><surname>Zinchuk</surname><given-names>A</given-names></string-name>, <etal/></person-group>. <article-title>Correlates of sleep quality and excessive daytime sleepiness in people with opioid use disorder receiving methadone treatment</article-title>. <source>Sleep Breath</source>. <year>2020</year>;<volume>24</volume>(<issue>4</issue>):<fpage>1729</fpage>-<lpage>1737</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-020-02123-z</pub-id><?supplied-pmid 32556918?><pub-id pub-id-type="pmid">32556918</pub-id></mixed-citation>
              </ref>
              <ref id="zoi230235r61">
                <label>61</label>
                <mixed-citation publication-type="journal"><person-group><string-name><surname>Jiang</surname><given-names>B</given-names></string-name>, <string-name><surname>He</surname><given-names>D</given-names></string-name>, <string-name><surname>Guo</surname><given-names>Z</given-names></string-name>, <string-name><surname>Gao</surname><given-names>Z</given-names></string-name></person-group>. <article-title>Dynamic features of placebo effects addressing persistent insomnia disorder: a meta-analysis of placebo-controlled randomized clinical trials</article-title>. <source>J Sleep Res</source>. <year>2020</year>;<volume>29</volume>(<issue>4</issue>):<elocation-id>e12997</elocation-id>. doi:<pub-id pub-id-type="doi">10.1111/jsr.12997</pub-id><?supplied-pmid 32052501?><pub-id pub-id-type="pmid">32052501</pub-id></mixed-citation>
              </ref>
            </ref-list>
            <notes notes-type="supplementary-material" id="note-ZOI230235-1">
              <supplementary-material id="note-ZOI230235-1-s" position="float" content-type="local-data">
                <label>Supplement 1.</label>
                <caption>
                  <p>
Trial Protocol and Statistical Analysis Plan
</p>
                </caption>
                <media xlink:href="jamanetwopen-e237099-s001.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 2.</label>
                <caption>
                  <p><bold>eTable.</bold> Observed (Raw) Means of Secondary Outcomes at Each Time Point: Drug Use, Withdrawal, Craving, Quality of Life, and Sleep (TAU, n = 54; C-OLP, n = 77)</p>
                </caption>
                <media xlink:href="jamanetwopen-e237099-s002.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
              <supplementary-material position="float" content-type="local-data">
                <label>Supplement 3.</label>
                <caption>
                  <p>
Data Sharing Statement
</p>
                </caption>
                <media xlink:href="jamanetwopen-e237099-s003.pdf">
                  <caption>
                    <p>Click here for additional data file.</p>
                  </caption>
                </media>
              </supplementary-material>
            </notes>
          </back>
        </article>
      </metadata>
    </record>
  </GetRecord>
</OAI-PMH>
